|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||4.60 - 4.76|
|52 Week Range||2.27 - 6.43|
|Beta (3Y Monthly)||1.07|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.12|
SAN JOSE, Calif., Sept. 28, 2018 /PRNewswire/ -- ITUS Corporation (the "Company") (ITUS), a biotechnology company focused on using the body's immune system to fight cancer, today announced that on October 1, 2018, the Company will officially change its name to Anixa Biosciences, Inc. Effective at the start of trading on October 1, 2018, the Company's shares will trade on the NASDAQ Capital Market under the new name, and the new stock symbol will be "ANIX." The Company's website will be accessible at www.anixa.com.
SAN JOSE, Calif., Sept. 5, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) and its research partner, Moffitt Cancer Center, today announced that a pre-IND meeting with the US FDA has been scheduled on Tuesday, October 16, 2018. The meeting is to discuss numerous aspects of the planned clinical trial of their CAR-T therapy for ovarian cancer. Dr. Amit Kumar, CEO of ITUS stated, "We are pleased to be meeting with the FDA this fall, as anticipated. We have submitted pre-clinical data, as well as a series of questions, to the FDA. Coming out of this meeting, our goal is to have a good understanding of the design for the clinical trial in our Investigational New Drug (IND) application.
SAN JOSE, Calif., Aug. 17, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) today announced that CEO, Dr. Amit Kumar, will be presenting at the Next Generation Dx Summit in Washington, D.C., being held on August 20th-24th. Dr. Kumar's presentation, "Liquid Biopsy based on Flow Cytometry and Artificial Intelligence to Detect the Existence of a Solid Tumor," is scheduled at 2:50 PM EDT, Wednesday, August 22nd. Dr. Kumar will discuss ITUS's latest data on its Cchek™ diagnostic development, including studies on breast cancer and prostate cancer, as well as data from the collaborative study with Memorial Sloan Kettering and Serametrix.
This meeting, known as a pre-IND meeting, is designed to enable drug developers and the FDA to evaluate a drug's pre-clinical data and its proposed development path in anticipation of filing an Investigational New Drug (IND) application. ITUS and Moffitt have previously stated that this program is ahead of schedule. Assuming the FDA does not require additional animal studies, ITUS and Moffitt hope to file the IND application in early 2019 and begin human trials once approved by the FDA.
The Cchek™ breast cancer study is focused on early stage cancer, because other methods are poor at accurately identifying stage 1 and 2 malignancies. The interim results showed sensitivity of 92% and specificity of 87% for stage 1 and 2 cancers. The interim data utilized blood samples from a total of 144 patients, that included 64 women who had biopsy verified breast cancer, and 80 women with no cancer. Our AI application was trained with 88 patients and tested with 56. As later stage patients are added to the study, performance is expected to improve.
SAN JOSE, Calif. , July 6, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that due to the significance of positive results as well as strong commercial interest, it has selected breast ...
ITUS recently announced that the CAR-T therapy for ovarian cancer, being developed in collaboration with The Moffitt Cancer Center, is roughly one year ahead of its original development timeline, and the Company anticipates a pre-IND meeting with the US FDA in the October/November timeframe. Assuming the FDA does not require significant additional animal studies, the IND application could be filed as soon as Q1 of 2019 with human trials beginning as early as the first half of 2019. The event can be viewed live by visiting https://new.livestream.com/nasdaq/live.
SAN JOSE, Calif., June 26, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) today provided a status update and accelerated development timeline for its CAR T therapy for Ovarian Cancer, which is in development with Moffitt Cancer Center. ITUS initiated a Cooperative R&D Agreement (CRADA) with Moffitt to advance a proprietary CAR T therapy for ovarian cancer in November 2017. The study is led by Jose Conejo-Garcia, M.D., Ph.D., Chair of the Department of Immunology at Moffitt. The aim of this CRADA is to complete the pre-clinical studies necessary for the submission of an IND application to the FDA, seeking approval to test the therapy in human patients. The previous goal for IND submission was the end of 2019 or early 2020, now it has been accelerated dramatically.
SAN JOSE, Calif. , June 13, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that it has chosen prostate cancer as the first commercial focus for its Cchek™, non-invasive liquid biopsy ...
CORAL SPRINGS, FL / ACCESSWIRE / June 12, 2018 / Cancer is a devastating illness that affects a large population of patients in the United States. In fact, it is estimated by the National Cancer Institute that in the year 2018 alone, 1.73535 million patients will be diagnosed with cancer and 609,640 Americans will succumb to the ailment. At the helm of innovation in the cancer diagnostics and immunotherapy markets, we find ITUS Corp. (NASDAQ: ITUS).
Research reports have been issued by WallStEquities.com on Fiserv Inc. (NASDAQ: FISV), FleetCor Technologies Inc. (NYSE: FLT), Genpact Ltd (NYSE: G), and ITUS Corp. (NASDAQ: ITUS). Companies in the Business Services sector provide support services, such as office administration, hiring and placing of personnel, security services, travel arrangement, cleaning, and waste disposal, to businesses.
Today, I will be analyzing ITUS Corporation’s (NASDAQ:ITUS) recent ownership structure, an important but not-so-popular subject among individual investors. The impact of a company’s ownership structure affects both its short-Read More...
NEW YORK, NY / ACCESSWIRE / May 1, 2018 / ITUS Corporation (NASDAQ: ITUS) announced today that it will be presenting at the 3 rd annual Disruptive Growth & Healthcare Conference on Tuesday, May 8 th at ...
SAN JOSE, Calif., April 2, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) today announced that the presentation given by its Chief Executive Officer, Dr. Amit Kumar, at its Special Meeting of Stockholders on March 29, 2018 has been placed on the Company's website. It can be viewed at http://ir.ituscorp.com/corporate-presentation.
SAN JOSE, Calif., March, 27, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) today announced that it has completed a prostate cancer study with Serametrix in which data from a previous collaboration between Serametrix and Memorial Sloan Kettering Cancer Center (MSK) was re-evaluated using ITUS technology.
SAN JOSE, Calif. , March 26, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), a company using the power of the immune system to diagnose and treat cancer, today announced that the United States Patent ...
When ITUS Corporation (NASDAQ:ITUS) released its most recent earnings update (31 January 2018), I compared it against two factor: its historical earnings track record, and the performance of its industryRead More...
SAN JOSE, Calif. , March 16, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), today announced that it will present the latest data from its ongoing early cancer detection study at the annual meeting ...
SAN JOSE, Calif., March 12, 2018 /PRNewswire/ -- ITUS Corporation (ITUS), today announced that it will present data from its ongoing study utilizing Cchek™, ITUS's artificial intelligence (AI) driven early cancer detection technology. The presentation will be made at the annual meeting of the American Association of Cancer Research (AACR) in Chicago, Illinois. The meeting will be held April 14-18, 2018 and will be attended by world leading experts across the field of cancer research. All abstracts will be viewable by registered attendees beginning March 14, 2018. To receive a copy of the presentation, please email your request to AACR-2018@ITUScorp.com starting April 19, 2018 and include your name, title, and contact information. The presentation will focus on ITUS' proprietary Cchek™ platform featuring new data and insights into this early cancer detection technology. Cchek™ combines the immunophenotyping of white blood cells using flow cytometry with a proprietary neural network, a type of artificial intelligence (AI), to detect the presence of solid tumors from a blood sample. Identifying and measuring circulating myeloid-derived suppressor cells (MDSCs), a group of immunosuppressive white blood cells, is the foundation of this technology.
SAN JOSE, Calif. , March 9, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that John Roop , Senior Vice President of Engineering is scheduled to present on Friday March 16, 2018 , ...
SAN JOSE, Calif., March 5, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) today announced that ITUS and Serametrix Corporation have signed an agreement to bring the power of Cchek™, ITUS's proprietary, AI-driven liquid biopsy cancer diagnostic technology to Serametrix's substantial expertise in immune monitoring assays. Serametrix flow cytometry and related data analysis services are already widely used in immunotherapy drug trials.
SAN JOSE, Calif., Feb. 7, 2018 /PRNewswire/ -- ITUS Corporation (ITUS), today announced that its presentation titled, "The coupling of MDSCs with a computational analytic method to detect solid tumors," has been accepted for presentation at the Keystone Symposia Conference - Cancer Immunotherapy: Combinations in Montreal, Quebec, Canada. Myeloid-derived suppressor cells, or MDSCs, are a key group of white blood cells that form the foundation for ITUS' liquid biopsy technology. The presentation will focus on ITUS' proprietary Cchek™ platform which utilizes immuno-profiling via Flow Cytometry and Artificial Intelligence to enable the detection of solid tumors from a blood sample.
Stock Monitor: Alliance Data Systems Post Earnings Reporting LONDON, UK / ACCESSWIRE / January 31, 2018 / Active-Investors.com has just released a free research report on ITUS Corp. (NASDAQ: ITUS ).If ...
Levi & Korsinsky announces it has commenced an investigation of ITUS Corporation concerning possible breaches of fiduciary duty. To obtain additional information